Course1

22nd Annual Berkeley-Stanford Advanced Patent Law Institute - Managing international patent prosecution

  • Author/Instructor:  BCLT

Co-organized with Stanford Law School, the APLI presents a roster of judges, academics, litigators, patent prosecutors, and senior IP counsel from major corporations offering a results-oriented, in-depth look at the latest developments in patent law and practice. Speakers Ken Korea, Colev LawHolly Logue, HolmuskMark Mathison, Kilpatrick TownsendAllison Schmitt, BCLT (Moderator    

  • On-Demand
    Format
  • 45
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

22nd Annual Berkeley-Stanford Advanced Patent Law Institute - Prosecution uncertainty: Thoughts about planning (...)

  • Author/Instructor:  BCLT

22nd Annual Berkeley-Stanford Advanced Patent Law Institute - Prosecution uncertainty: Thoughts about planning for the long game Co-organized with Stanford Law School, the APLI presents a roster of judges, academics, litigators, patent prosecutors, and senior IP counsel from major corporations offering a results-oriented, in-depth look at the latest developments in patent law and practice. Speakers Lora Green, Wilson SonsiniBrian Hickman, Hickman BeckerWilliam James, Van Pelt, Yi & JamesGilbert Wong, Facebook    

  • On-Demand
    Format
  • 45
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

Advanced Life Sciences Institute - Carving Out Induced Infringement: Strategy for Skinny Labels

  • Author/Instructor:  BCLT

BCLT’s new Life Sciences Project is thrilled to announce the launch of our Advanced Life Sciences Institute. We are very excited to be kicking this new program off on April 22, 2022, with a conference on IP and licensing. Join us for in-depth discussions and examination of key issues related to intellectual property and transactions in the life sciences sector. Learn from the life sciences legal experts! CLE will be offered. Speakers: Kira Davis, Durie TangriAzra Hadzimehmedovic, TensegrityRyan Johnson, Fenwick    

  • On-Demand
    Format
  • 45
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

Advanced Life Sciences Institute - Facilitating Collaboration in the Life Sciences – Funding, Licensing, and International Collaboration

  • Author/Instructor:  BCLT

BCLT’s new Life Sciences Project is thrilled to announce the launch of our Advanced Life Sciences Institute. We are very excited to be kicking this new program off on April 22, 2022, with a conference on IP and licensing. Join us for in-depth discussions and examination of key issues related to intellectual property and transactions in the life sciences sector. Learn from the life sciences legal experts! CLE will be offered. Speakers: Kate Hillier, Cooley Ryan Murr, Gibson Dunn Margaret Sampson, Baker Botts    

  • On-Demand
    Format
  • 45
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

Advanced Life Sciences Institute - Protecting and Licensing AI Inventions in the Life Sciences

  • Author/Instructor:  BCLT

BCLT’s new Life Sciences Project is thrilled to announce the launch of our Advanced Life Sciences Institute. We are very excited to be kicking this new program off on April 22, 2022, with a conference on IP and licensing. Join us for in-depth discussions and examination of key issues related to intellectual property and transactions in the life sciences sector. Learn from the life sciences legal experts! CLE will be offered. Speakers: Hogene Choi, Morrison & Foerster Hans Sauer, BIO Bruce Wexler, Paul Hastings Andrew Whitehead, Genentech

  • On-Demand
    Format
  • 45
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

Advanced Life Sciences Institute - Protecting IP and Litigating into Uncertainty: Challenges from Sections 101 and 112 in the Life (...)

  • Author/Instructor:  BCLT

Advanced Life Sciences Institute - Protecting IP and Litigating into Uncertainty: Challenges from Sections 101 and 112 in the Life Sciences BCLT’s new Life Sciences Project is thrilled to announce the launch of our Advanced Life Sciences Institute. We are very excited to be kicking this new program off on April 22, 2022, with a conference on IP and licensing. Join us for in-depth discussions and examination of key issues related to intellectual property and transactions in the life sciences sector. Learn from the life sciences legal experts! CLE will be offered. Speakers: Natalie Derzko, Covington & Burling Colleen Tracy James, White & Case Eugene Novikov, Durie Tangri Richard Torczon, Wilson Sonsini  

  • On-Demand
    Format
  • 45
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

Advanced Life Sciences Institute - The Judicial Perspective

  • Author/Instructor:  BCLT

BCLT’s new Life Sciences Project is thrilled to announce the launch of our Advanced Life Sciences Institute. We are very excited to be kicking this new program off on April 22, 2022, with a conference on IP and licensing. Join us for in-depth discussions and examination of key issues related to intellectual property and transactions in the life sciences sector. Learn from the life sciences legal experts! CLE will be offered. Speakers: Jeremy Fogel, Berkeley Law / Berkeley Judicial Institute (moderator)Judge Stanley Chesler, District of New JerseyJudge Beth Freeman, Northern District of CaliforniaJudge Kathleen O’Malley, U.S. Court of Appeals, Fed. Cir. (ret)Judge Leonard Stark, U.S. Court of Appeals, Fed. Cir.  

  • On-Demand
    Format
  • 75
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

Berkeley IP Tech and Law Month: Biometric Law Year in Review

  • Author/Instructor:  BCLT

As part of Berkeley IP Tech & Law month, our instructors take you through the key highlights from the last year in Berkeley IP Tech and Law Month: Biometric Law Year in Review. Speakers: Nicole Ozer , ACLU Maneesha Mithal , Wilson Sonsini Goodrich & Rosati

  • On-Demand
    Format
  • 60
    Min.
  • 5/1/23
    Avail. to
  • DETAILS
Course1

BTLJ-CMTL-BCLT Symposium | Race & Technology Law: Innovating Health Equity

  • Author/Instructor:  BCLT

The nexus of technology and the law has played a major role in amplifying racial injustices in many of society’s institutions. The global COVID-19 pandemic has exacerbated pre-existing racial disparities in medicine, shedding light on the ways in which technology and the law impact equitable access to healthcare. But technology and the law can also be instruments for structural change. As future lawyers, the student leaders of the Berkeley Technology Law Journal (BTLJ) and the Coalition of Minorities in Tech Law (CMTL) are eager to examine race, health equity, and the effects of technological innovation on communities of color. Therefore, we are convening this special symposium with the Berkeley Center for Law and Technology (BCLT). Last fall, the first annual BTLJ-BCLT Race & Technology Law Symposium broached a variety of tech law topics as they intersect with race. This year, the Symposium focuses on how race, technology, and the law intersect in the healthcare space. We have invited leading and rising legal academics to share their research and perspectives on the intersection of technology, law, and race within the American healthcare system. In conversation with one another, they will help us explore and propose options for anti-racist paths forward for the fields of technology law and healthcare. We have entitled this symposium: “Race & Technology Law: Innovating Health Equity.” Our panels will highlight a variety of tech law topics as they intersect with race and healthcare. A few of these topics include: -Access to healthcare innovation -Telehealth medicine -Reproductive rights -Eugenics and CRISPR-Cas9 technology Speakers: Sharona Hoffman, Edgar A. Hahn Professor of LawCarol McCall, Chief Health Analytics Officer at ClosedLoop.aiChristopher Morten, Columbia Law SchoolFabiola Carrión, National Health Law ProgramPeyten Sharp, Akin GumpDayna Bowen Matthew, George Washington University Law SchoolJohn Evans, Institute for Practical Ethics at University of California, San DiegoPeter Groeneveld, University of Pennsylvania’s Perelman School of MedicineOsagie K. Obasogie, University of CaliforniaTahir Amin, I-MAKWendy Epstein, DePaul College of LawJimmy Sanders, Gunderson Dettmer  

  • On-Demand
    Format
  • 60
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

Carving out Induced Infringement: Update on Skinny Labels

  • Author/Instructor:  BCLT

These expert-led discussions are designed to ensure you are up-to-date and prepared for the in-depth strategy discussions at the in-person conference on April 22. Join us for a discussion on the latest issues in induced infringement (including skinny labels) on April 6, as well as a discussion of the complicated landscape of Section 112 law in the life sciences on April 13. Speakers Mila Owen, White & CaseAllison Schmitt, BCLT  

  • On-Demand
    Format
  • 30
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

China Stakes Out Its Place in Plant Variety Protection: An Update with Experts on PVP and Agricultural IP Developments (...)

  • Author/Instructor:  BCLT

China Stakes Out Its Place in Plant Variety Protection: An Update with Experts on PVP and Agricultural IP Developments in China Article 14 Any plant variety in respect of which variety rights are granted shall have the characteristic of novelty. Novelty means that the propagating material of the new plant variety in respect of which variety rights are applied for has not been sold prior to the filing date of the application, or has not been for sale, with the consent of the breeder, for more than one year within the territory of China; the propagating material of vines, forest trees, fruit trees and ornamental plants must not have been for sale for more than six years, or the propagating material of other plant varieties for more than four years, in a foreign territory. As always please consult counsel for specific legal advice. Since China established its legal regime for the protection of new varieties of plants in 1997, it has emerged as the country with the largest number of plant variety applications in the world, as well as the most litigious.  China’s current plant variety regime focuses on policy and legislative initiatives, including work on a new Seed Law by the National People’s Congress. Its plant variety protection enforcement efforts also reflect many of the reforms already undertaken in other areas of IP law, including: providing for punitive damages, burden of proof reversals and exceptions and limitations to infringement. Yet, China has yet to accede to UPOV ’91, the latest version of the WIPO treaty to protect plant varieties.  To what extent does China’s plant variety IP regime address China’s twin goals of becoming an agricultural innovator and meeting the food security needs of its vast population? We will explore the public policy implications of China’s efforts to become a major force in new plant varieties, the technical aspects of China’s emerging plant variety regime, and how these changes fit into China’s overall IP practice. Speakers Elaine Wu, USPTOAmy Martin, Driscoll’sDan Fang, American Seed Trade AssociationXu Yi, Lusheng Law FirmZhou Yanhao, Sinochem/SyngentaAlanna Rennie, Baker McKenzieMark A Cohen, BCLT/Berkeley LawMichael Ward, Morrison Foerster

  • On-Demand
    Format
  • 60
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

China: A Patent Linkage Update

  • Author/Instructor:  BCLT

Description China committed to a patent linkage (Hatch-Waxman) regime linking pharmaceutical regulatory approval and patent infringement determinations in the Phase 1 Trade Agreement concluded with the United States in January 2020. The linkage regime is part of a series of pharmaceutical IP related reforms set forth in that Agreement. With the enactment of China’s revised patent law, as well as the adoption of new rules on patent linkage on July 4, 2021 and a new Judicial Interpretation on July 5, 2021, the basic legislative framework for China’s new patent linkage regime is now in place. But how will these new rules work in practice? Speakers Mark Cohen, BCLT/Berkeley Law (Moderator)John Balzano, CovingtonDouglas Clark, Rouse (Hong Kong)Jill Ge, Allen & Overy (Shanghai)He Jing, Genlaw (Beijing)Judge Randall R. Rader (ret.)    

  • On-Demand
    Format
  • 90
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

EPO insights directly from the EPO

  • Author/Instructor:  BCLT

What do the filings tell us about which countries and which companies are focusing on AI, semiconductors, and medical devices?  Patent-filing data reveals a great deal about global competition and global R&D focus. Based on data from the EPO, this program gives unique insight into what is happening in AI, semiconductors, and medical devices.  Learn where countries and companies are focusing their efforts.  This is Session 1 of a series.   Speakers Gwilym Roberts Aiden Kendrick QUESTIONS FOR THE INSTRUCTORS? Reach out to them directly through LinkedIn by following the links above.

  • On-Demand
    Format
  • 60
    Min.
  • 1/26/24
    Avail. to
  • DETAILS
Course1

Protecting IP and Litigating into Uncertainty: Update on Application of Section 112

  • Author/Instructor:  BCLT

These expert-led discussions are designed to ensure you are up-to-date and prepared for the in-depth strategy discussions at the in-person conference on April 22. Join us for a discussion on the latest issues in induced infringement (including skinny labels) on April 6, as well as a discussion of the complicated landscape of Section 112 law in the life sciences on April 13. Speakers Priyata Patel, Weil GotshalAllison Schmitt, BCLT

  • On-Demand
    Format
  • 30
    Min.
  • 1/1/24
    Avail. to
  • DETAILS
Course1

The USPTO-FDA Collaboration: Laying the Foundation for the Life Sciences Industry and Beyond

  • Author/Instructor:  BCLT

In 2021, President Biden called for action “to help ensure the patent system, while incentivizing innovation, does not also unjustifiably delay generic drug and biosimilar competition beyond that reasonably contemplated by applicable law.” In response, the USPTO and the FDA have begun an unprecedented collaboration that the USPTO believes will “strengthen our patent system for all technologies.” This webinar will explore the first steps of that collaboration and possible next steps, including:   The USPTO’s notice on duties of disclosure and reasonable inquiry, particularly with respect to statements made to the FDA. The FDA’s (and some senators’) concerns about continuation practice and the USPTO’s request for comments on that issue. The role of the PTAB in the collaboration, including the interplay between post grant proceedings at the PTAB and Orange-book listed patents and biologic patents. The webinar will include a diverse panel of stakeholders, including Deputy Chief Judge Mike Tierney and Deputy Commissioner Bob Bahr of the USPTO and former FDA Chief Counsel Stacy Amin.   Speakers Linda Horner – Chief Judge, USPTO Bob Bahr – Deputy Commissioner, USPTO Mehran Arjomand– Partner, Morrison Foerster Stacy Amin – Former FDA Chief Counsel, Partner, Morrison Foerster Dr. Jean Nguyen – Associate, Morrison Foerster   --- B-CLE is only certified to give credit for California. If you are seeking credit for another jurisdiction, please check with your state bar to determine if California CLE credits are recognized, through reciprocity, in your jurisdiction.   Directions: Viewing on our B-CLE platform is completely complementary. To access the course, click "Add to Cart", then go to "Check Out". Afterwards, click "Order Free Program(s)". The course will then be ready On-Demand.

  • On-Demand
    Format
  • 60
    Min.
  • 5/16/24
    Avail. to
  • DETAILS
Course1

What your IP Attorney Wishes You'd Known Before Starting Your Company

  • Author/Instructor:  BCLT

You've identified an unmet need in the life sciences or healthcare space, and developed a clever solution. You're ready to move forward in commercializing your solution into a product, but you will need funding and partnerships to succeed. How can you set yourself up for success--in particular, what do you need to know about your IP landscape and protection strategy, before meeting with potential partners and funders?   Speakers: Ali R. Alemozafar, PhD, Wilson Sonsini Goodrich & Rosati Maria Faradis, PhD, Venture Partner Neena Kadaba, PhD, Apple Tree Partners Uri Lpoatin, MD, Pardes Biosciences Greg Went, PhD, Reflextions Pharmaceuticals    

  • On-Demand
    Format
  • 60
    Min.
  • 5/17/24
    Avail. to
  • DETAILS